SOCIETY OF HEMATOLOGIC ONCOLOGY
SOHO 2023September 6-9, 2023 Houston
N. Poster
Poster title
Applicant name
Status
 |
|
|
|
| ABCL-004 | Salvage Radiotherapy in Relapsed/Refractory Large B-Cell Lymphoma After CAR T-Cell Therapy Failure | Hazim Ababneh |  Received |
 |
|||
| MDS-008 | Impact of Timing of Achievement of Red Blood Cell-Transfusion Independence (RBC-TI) on Clinical Outcomes and Resource Utilization in Lower-Risk Myelodysplastic Syndromes (LR-MDS) | Taani Taufa | Received |
|
|||
| MDS-009 | Enhanced Survival of Chronic Myelomonocytic Leukemia (CMML)-Dysplastic Over the Proliferative Subtype After Allogeneic Hematopoietic Cell Transplantation: A Tertiary Center Experience | Yazan Migdady | Received |
|
|||
| MM-028 | Treatment Efficacy for Relapsed and Refractory Multiple Myeloma Patients With Gain or Amplification of 1q21: A Systematic Review and Meta-Analysis of Randomised Controlled Trials | zhanzhi xie | Received |
|
|||
| ALL-040 | Hispanic Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Had Worse Overall Survival in a Minority Predominant Cohort | Karun Neupane | Received |
|
|||
| ABCL-041 | Clinicopathological Profile of Lymphoma in a Tertiary Center in Nepal | Pandey Shama | Received |
|
|||
| CT-045 | Primary results from OUTREACH: a phase 2 study of lisocabtagene maraleucel administered in the communitysetting as outpatient or inpatient treatment in patients with relapsed or refractory large B-cell lymphoma | Alex Medaglia | Received |
|
|||
| AML-047 | Risk Factors Beyond Chemotherapy Exposure for Therapy-Related Myelodysplastic Syndrome (tMDS) and Acute Myeloid Leukemia (tAML) Development in Lymphoma Survivors: A 15-year SEER-Medicare Analysis | Herr Megan | Received |
|
|||
| MDS-65 | Treatment Patterns and Transfusion Outcomes Among Erythropoietin-Stimulating Agent (ESA)-Naïve Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Receiving Luspatercept in Routine Clinical Practice in the United States (US) | Taani Taufa | Received |
|
|||
| MDS-067 | First-Line (1L) Treatment Patterns and Outcomes Among Patients With Newly Diagnosed Myelodysplastic Syndromes (MDS): A Global, Retrospective Observational Cohort Study | Taani Taufa | Received |
|
|||
| MPN-070 | Real-World Clinical Outcomes in Patients with Myelofibrosis (MF) Previously Treated with Ruxolitinib (RUX) | Taani Taufa | Received |
|
|||
| MDS-071 | Luspatercept restores effective erythropoiesis and provides superior and sustained clinical benefi t versus epoetin alfa:biomarker analysis from the phase 3 COMMANDS study | Heather Duffy | Received |
|
|||
| MPN-073 | Development of a Diagnostic Algorithm for the Early Identification of Patients With Systemic Mastocytosis | Powell Dakota | Received |
|
|||
| MM-074 | How can Different Therapeutic Strategies and Financial Resources Impact Outcomes After Autologous Stem Cell Transplantation in Myeloma? Study in France and Algeria | Michallet Mauricette | Received |
|
|||
| IBCL-078 | Histiocytic Sarcoma Presenting as Nodular Skin Lesion on the Anterior Chest In a 38-Year-Old Woman: A Case Report | Nina Ricci Sampana | Received |
|
|||
| CLL-079 | The Effect of T-Lymphocyte Subgroups at Diagnosis on the Prognosis of Chronic Lymphocytic Leukemia (CLL) | Seyithanoglu Deniz | Received |
|
|||
| AML-080 | Modeling Flotetuzumab-Associated Cytokine Release Syndrome (CRS) in AML Using In Vitro and In Vivo Preclinical Models | Dilan Patel | Received |
|
|||
| CLL-081 | Impact of Multi-Hit vs Single-Hit TP53 Mutations in Chronic Lymphocytic Leukemia | Steven Hwang | Received |
|
|||
| CT-083 | Epidemiological and Clinical Data in Low- and Intermediate-Risk Neuroblastoma: A Single Institution Experience and Survival Outcomes in Jerusalem | Sbeih Ala | Received |
|
|||
| MPN-91 | Indirect Treatment Comparison of Momelotinib vs Fedratinib Safety in Patients With Myelofibrosis | Michael Checkoway | Received |
|
|||
| MPN-92 | Indirect Treatment Comparisons of Momelotinib vs Pacritinib Safety and Anemia Outcomes in Patients With Myelofibrosis | Michael Checkoway | Received |
|
|||
| MPN-93 | Impact of Transfusion Burden on Health-Related Quality of Life and Functioning in Patients With Myelofibrosis: Post Hoc Analysis of SIMPLIFY-1 and -2 | Michael Checkoway | Received |
|
|||
| CLL-094 | Lisocabtagene maraleucel in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: primary analysis of the phase 1/2, single-arm, multicenter TRANSCEND CLL 004 study | Alex Medaglia | Received |
|
|||
| MCL-096 | Lisocabtagene maraleucel in R/R MCL: primary analysis results from the MCL cohort of the single-arm, multicenter, phase 1 seamless design TRANSCEND NHL 001 study | Alex Medaglia | Received |
|
|||
| IBCL-098 | TRANSCEND FL: Phase II Study Results of Lisocabtagene Maraleucel (Liso-Cel) in Patients With R/R Follicular Lymphoma (FL) | Alex Medaglia | Received |
|
|||
| IBCL-099 | Intensive Chemotherapy and Autologous Stem Cell (ASCT) Consolidation for Bing Neel Syndrome | Khwaja Jahanzaib | Received |
|
|||
| CT-105 | Post-infusion monitoring costs and health care resource utilization by site of care in patients with relapsed or refractory chronic lymphocytic leukemia receiving lisocabtagene maraleucel treatment in the TRANSCEND CLL 004 study | Alex Medaglia | Received |
|
|||
| CT-107 | Cost-effectiveness of the chimeric antigen receptor T cell treatments, lisocabtagene maraleucel versus axicabtagene ciloleucel, as second-line treatment of large B-cell lymphoma | Alex Medaglia | Received |
|
|||
| MPN-111 | SVR (Spleen Volume Reduction) Predicts OS (Overall Survival) in MF (Myelofibrosis) Patients on PAC (Pacritinib) but Not BAT (Best Available Therapy): PERSIST-2 Landmark OS Analysis | Phoebe Davis | Received |
|
|||
| MPN-133 | Reduction in Red Blood Cell Transfusion Burden: A Novel Longitudinal Time-Dependent Analysis in Patients With Transfusion-Dependent Myelofibrosis Treated With Momelotinib | Michael Checkoway | Received |
|
|||
| MCL-155 | Pirtobrutinib in Covalent BTK Inhibitor Pre-Treated Mantle Cell Lymphoma: Updated Results and Subgroup Analysis from the Phase 1/2 BRUIN Study With 3 Years Follow-up from Start of Enrollment | Michael Wang | Received |
|
|||
| MDS-156 | Pyrimethamine Shows Synergy and Efficacy in Combination With Venetoclax in Preclinical Models of Therapy Resistant MDS/AML | Rivera-Peña Bianca | Received |
|
|||
| MDS-157 | Luspatercept versus epoetin alfa for treatment of anemia in patients with erythropoiesis-stimulating agent-naive lower-risk myelodysplastic syndromes requiring red blood cell transfusions: data from the phase 3 COMMANDS study | Heather Duffy | Received |
|
|||
| MM-161 | Talquetamab Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Updated TRIMM-2 Results | Kristen Senn | Received |
|
|||
| MM-162 | Durability of Responses With Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma Achieving a Clinical Response in the MajesTEC-1 Study | Kristen Senn | Received |
|
|||
| MM-163 | Long-Term Follow-up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) | Kristen Senn | Received |
|
|||
| MM-164 | First Results From the RedirecTT-1 Study With Teclistamab (Tec) Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) | Kristen Senn | Received |
|
|||
| CT-166 | Long-term Safety With =12 Months of Pirtobrutinib in Relapsed/Refractory B-Cell Malignancies | Catherine Muehlenbein | Received |
|
|||
| CT-168 | Comparison of Bleeding-Related Events in Patients Who Received Pirtobrutinib With and Without Antithrombotic Agents | Heiko Konig | Received |
|
|||
| AML-178 | A Multi-institutional Analysis of Outcomes in Acute Myeloid Leukemia Patients With Central Nervous System Involvement | Dahniel Sastow | Received |
|
|||
| ABCL-180 | Targeting Homologous Recombination Deficiencies in B-Cell Non-Hodgkins Lymphomas with the Novel Anti-Tumor Small Molecule LP-284 | Zhou Jianli | Received |
|
|||
| MM-182 | Allocation and Validation of the Second Revision of the International Staging System in the ICARIA-MM and IKEMA Studies | Rajani Singh | Received |
|
|||
| MM-191 | Analysis of Infections and Parameters of Humoral Immunity in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Talquetamab (tal) Monotherapy in MonumenTAL-1 | Kristen Senn | Received |
|
|||
| MM-192 | Preliminary Recommendations for Prevention and Management of Infections, Hypogammaglobulinemia, and Neutropenia During Treatment With Teclistamab Based on Experience From the MajesTEC-1 Study | Kristen Senn | Received |
|
|||
| MPN-193 | Incidence of Blast Phase in Myelofibrosis According to Anemia Severity | Mora Barbara | Received |
|
|||
| CLL-194 | Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison of 3 Randomized Phase III Trials | PCYC Publications | Received |
|
|||
| MDS-195 | Characterization of Patients with Co-Occurrent Clonal Myeloid and Plasma Cell Disorders: A Single Center Descriptive Case Series | Michael Hochman | Received |
|
|||
| AML-197 | Clinical outcomes and treatment patterns in adult patients with FMS-like tyrosine kinase 3 internal tandem duplication positive acute myeloid leukemia undergoing allogeneic hemopoietic cell transplantation in the US and Canada: Center for International Blood and Marrow Transplant Research analysis | Jaymini Patel | Received |
|
|||
| MDS-198 | Early Bone Marrow Transplantation in GATA2 Deficiency-Induced Myelodysplastic Neoplasms | Nino Totogashvili | Received |
|
|||
| AML-204 | Thrombocytopenia Mimicking an Unusual Myelotoxicity Post Standard Cytotoxic Chemotherapy in Ovarian Cancer | El Murr Lina | Received |
|
|||
| IBCL-218 | Parotid Gland Extramedullary Hairy Cell Leukemia: A Case Report With Review of Literature | Mohammed Shafi Abdul Salam | Received |
|
|||
| AML-219 | Multi-Gene Molecular MRD by Digital PCR is Prognostic of Outcomes in AML Treated With Venetoclax/Azacitidine | Amanda Winters | Received |
|
|||
| AML-220 | Sinusitis as a Presentation of Acute Myeloid Leukemia (AML) and Myeloid Sarcoma (MS) | Fuentes-Alfaro Fabiola | Received |
|
|||
| TCL-221 | Hyper Eosinophilia with FIP1L1-PDGFRA Gen Fusion Presenting as a T-Cell Lymphoblastic Lymphoma | Monge Jose | Received |
|
|||
| MDS-234 | Reduction of transfusion burden, hemoglobin increase, and dose titration in the COMMANDS study of luspatercept versus epoetin alfa in erythropoietin-stimulating agent-naive patients with transfusion-dependent lower-risk myelodysplastic syndromes | Heather Duffy | Received |
|
|||
| MM-246 | Isatuximab (Isa) in Relapsed Multiple Myeloma (MM) Patients (pts) With Ultra-High-Risk (UHR) Cytogenetics: ICARIA-MM and IKEMA Subgroup Analysis | Rajani Singh | Received |
|
|||
| MM-248 | Long-Term Outcomes With Isatuximab-Carfilzomib-Dexamethasone (Isa-Kd) in Relapsed Multiple Myeloma (MM) Patients (pts) With 1q21 Status: Updated Results from the Phase 3 IKEMA Study | Rajani Singh | Received |
|
|||
| ALL-258 | Association of CXCR3 Receptor Chemokines Serum Levels With the Clinical Course of Febrile Neutropenia Among Children Treated for Cancer | Malgorzata Nowak | Received |
|
|||
| ALL-259 | Clinical and Molecular Features of Pediatric BCP-ALL with TSLP Receptor (CRLF2) Expression | Kolodrubiec Julia | Received |
|
|||
| TCL-263 | A Pilot Study of Siltuximab in Large Granular Lymphocytic Leukemia (LGLL) Trial in Progress | Ning Dong | Received |
|
|||
| IBCL-265 | Compassionate Use of Plitidepsin in Patients With Non-Hodgkin Lymphoma (NHL) and SARS-CoV-2 Infection | Lola Gomez Delgado | Received |
|
|||
| MDS-266 | A Comprehensive Assessment of the IPSS-M and Other Molecularly Integrated Risk Stratification Models in CMML | Luis E. Aguirre | Received |
|
|||
| ABCL-276 | Neurolymphomatosis: A Rare Presentation Mimicking a Schwannoma | Lina El Murr | Received |
|
|||
| AML-288 | The Result of Post Chemotherapy Bone Marrow Recovery in Patients With Acute Leukemia and Lymphoid Malignancies | Elbegjargal Erdenebaatar | Received |
|
|||
| MM-290 | Physician Perspectives Regarding Conventional Marrow Testing and Measurable Residual Disease (MRD) Assessments to Guide Decision-Making in Myeloma | Charlotte Williams | Received |
|
|||
| MPN-295 | Avapritinib in Patients With Advanced Systemic Mastocytosis (AdvSM): Efficacy and Safety Analyses from the Phase 2 PATHFINDER Study With 2-Year Follow-Up | Michelle Seddon | Received |
|
|||
| AML-299 | Azacitidine in Combination With Venetoclax for Myelodysplastic Syndrome (MDS) with Increased Blasts-2 in Clinical Practice Setting | Birute Davainiene | Received |
|
|||
| ALL-300 | First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia | Sara Cecere | Received |
|
|||
| MM-304 | Efficacy Outcomes and Characteristics of Patients With Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity After Treatment With Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1 | mary baugh | Received |
|
|||
| CML-305 | Discovery of a Selective PROTAC Degrading Untamable BCR::ABL1 Compound Mutants in Chronic Myelogenous Leukemia (CML )and Philadelphia ChromosomePositive (Ph) Acute Lymphoblastic Leukemia (ALL) | MILAD ROUHIMOGHADAM | Received |
|
|||
| MM-309 | CARTITUDE-1 Final Results: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma | Mary Baugh | Received |
|
|||
| CML-310 | Early Cytogenetic or Molecular Landmark Response to Ponatinib Treatment Predicts Outcomes in Heavily Pretreated Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in PACE: 5-Year Data | Sara Cecere | Received |
|
|||
| CML-313 | Post Hoc Analysis of Patient Responses by T315I Mutation Status From the 3-Year Update of the OPTIC Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib | Edlir Kaba | Received |
|
|||
| CML-315 | Assessment of Number Needed to Treat (NNT) and Cost per Response (CpR) in Patients (pts) With Relapsed/Refractory (R/R) Chronic Phase Chronic Myeloid Leukemia (CP-CML) Managed With Ponatinib (PON), Asciminib (ASC), and Bosutinib (BOS) | Sara Cecere | Received |
|
|||
| CML-319 | Molecular Response of =10 BCR::ABL1IS Is Predictive of Positive Outcomes in Patients With Treatment-Resistant Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Treated With Ponatinib From the Phase 2 OPTIC Trial | Edlir Kaba | Received |
|
|||
| ALL-327 | Inotuzumab Ozogamicin and Liver Toxicity: Something Old, Something New, and Something to Consider | Pham Bryan | Received |
|
|||
| MPN-336 | Selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve patients with myelofibrosis: Updated results and Subgroup Analyses from XPORT-MF-034 | Haris Ali | Received |
|
|||
| MPN-339 | Outcomes of Patients With Myelofibrosis and Elevated Peripheral Blood Blasts Treated With Pacritinib on Phase II/III Trials | Phoebe Davis | Received |
|
|||
| MDS-345 | Nature of Clinical Response and Depth of Molecular Response in Patients With TP53-Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Treated With Magrolimab With Azacitidine | Shannon Daugherty | Received |
|
|||
| MPN-346 | INDEPENDENCE: Enrolling Phase III Trial to Study the Efficacy and Safety of Luspatercept versus Placebo in Patients with Myelofibrosis on JAK2 Inhibitor (JAK2i) Therapy Requiring Red Blood Cell Transfusions (RBCTs) | Stephanie Wolfe | Received |
|
|||
| MDS-350 | Prognostic Impact of Lymphopenia in Myelodysplastic Neoplasms (MDS) | David Fandrei | Received |
|
|||
| MDS-355 | Work Productivity and Activity Impairment (WPAI), and Hemoglobin Levels During OPERA: a Real-World Study of Pegcetacoplan Treatment in US Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH) | Arnab Mondal | Received |
|
|||
| CT-356 | Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients with Triple-ClassExposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3, a Phase 3 Randomized Controlled Trial (RCT) | Michael Rowlands | Received |
|
|||
| MM-360 | Mezigdomide (MEZI) Plus Dexamethasone (DEX) in Relapsed/refractory Multiple Myeloma (RRMM): Results From the Dose-Expansion Phase of the CC-92480-MM-001 Trial | Taani Taufa | Received |
|
|||
| MDS-367 | A phase 2/3 trial of oral azacitidine in patients with low- or intermediate-risk myelodysplastic syndromes | Heather Duffy | Received |
|
|||
| AML-370 | Phase 1b OMNIVERSE trial: safety and tolerability of oral azacitidine in combination with venetoclax for treatment of acute myeloid leukemia | Heather Duffy | Received |
|
|||
| MM-371 | Pomalidomide, Daratumumab, and Dexamethasone After Lenalidomide Treatment in Patients With Relapsed or Refractory Multiple Myeloma (RRMM): Final Overall Survival (OS) Analysis of the Phase II MM-014 Study | Michael Rowlands | Received |
|
|||
| MM-372 | A Phase III, two-Stage, Randomized Study of Mezigdomide, Bortezomib, and Dexamethasone (MeziVd) Versus Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma (RRMM): SUCCESSOR-1 | Taani Taufa | Received |
|
|||
| MCL-373 | Unmet Need in Relapsed/refractory (RR) Mantle Cell Lymphoma (MCL) Post-Bruton Tyrosine Kinase Inhibitor (BTKi): Systematic Literature Review and Meta-Analysis | Michael Zoratti | Received |
|
|||
| AML-377 | Venetoclax in Combination With Low-Dose Cytarabine and/or Actinomycin D in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Patients With IDH1 or IDH2 Mutations | Guoda Daukelaite | Received |
|
|||
| MPN-380 | Interferon Alfa as a First- and Second-Line Treatment Option for Primary Myelofibrosis. | Daniel Zaldumbide | Received |
|
|||
| MPN-381 | BMS-986158, a Potent Bromodomain and Extraterminal Domain Inhibitor (BETi), as Monotherapy and in Combination With Ruxolitinib (RUX) or Fedratinib (FED) in Intermediate-Risk or High-Risk Myelofibrosis (MF): Results From a Phase I/II Study | Christopher Tehlirian | Received |
|
|||
| MPN-383 | Healthcare Resource Utilization and Costs Associated With Transfusion Dependence and Anemia Severity in Patients With Myelofibrosis: A Retrospective Analysis of the Medicare Fee-for-Service Claims Data | Michael Checkoway | Received |
|
|||
| IBCL-387 | Patient Characteristics and Treatment Patterns of US Medicare Fee-For-Service Beneficiaries With Waldenström Macroglobulinemia | Pharmacyclics Publications | Received |
|
|||
| MM-388 | Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients With Triple-ClassExposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): A KarMMa-3 Analysis in High-Risk Subgroups | Michael Rowlands | Received |
|
|||
| AML-400 | Outcomes of WT-1 (Wilms Tumor) Mutant Acute Myeloid Leukemia: Moffitt Cancer Center Experience | Jeremy DiGennaro | Received |
|
|||
| MDS-401 | Higher-Risk Myelodysplastic Neoplasms (HR-MDS) Patient Characteristics in a Large, Integrated United States (US) Healthcare System | Stephanie Gallagher | Received |
|
|||
| CLL-403 | Real-World Dosing Patterns and Time to Next Treatment for Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With or Without Ibrutinib Dose Reduction Following an Adverse Event | PCYC Publications | Received |
|
|||
| MPN-404 | Safety and Efficacy of Luspatercept for the Treatment of Anemia in Patients With Myelofibrosis: Results From the ACE-536-MF-001 Study | Michael Rowlands | Received |
|
|||
| AML-406 | Additional Risk Factors of Severe Bleeding in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML): Ukrainian Prospective Study in a Real-Life Cohort | Zinaida Stupakova | Received |
|
|||
| CML-418 | Determination of Treatment-Free Remission in Adult Patients with Chronic Myeloid Leukemia: Experience from an Institution in Western Mexico. | Jesús Manuel Ramírez Acuña | Received |
|
|||
| MDS-420 | Aplastic Anemia: Insight from a Single Center Experience | Parth Patel | Received |
|
|||
| TCL-423 | The Outcomes of Patients With T-Cell Prolymphocytic Leukemia After Allogenic Stem Cell Transplant: A Multicenter Retrospective Study | Mwanasha Merrill | Received |
|
|||
| CML-430 | Imatinib (IMA) Low Dose Reduction Program (LDRpro) in Chronic Myeloid Leukemia Ph in a Single Reference Institution in Mexico City. Open Prospective Study, 7 Years Follow-Up | Hurtado Rafael | Received |
|
|||
| MDS-432 | Challenges in Diagnosis and Treatment of VEXAS Syndrome: Two Case Reports | Sonia Raj | Received |
|
|||
| ABCL-433 | Treatment Outcomes of Patients With HIV-Associated High-Grade B-Cell Non-Hodgkin Lymphomas Treated With DA-EPOCH-R: Single Institutional Experience. | Daniel Zaldumbide | Received |
|
|||
| MM-438 | Addressing the Distress of Patients With Multiple Myeloma Can Improve Their Quality of Life, Parameters of Their Immune Profile and Autonomic Nervous System | Kotoucek Pavel | Received |
|
|||
| AML-443 | Clonal Evolution Analysis Using Next Generation Sequencing (NGS) Panel in a Cohort of 3,025 Patients With Acute Myeloid Leukemia (AML) | Colmenares Rafael | Received |
|
|||
| MM-445 | Genetic Abnormalities in a Real-World Cohort of Multiple Myeloma (MM) patients, and Their Impact on Outcomes: Single-Center Experience | Vilmante Vaitekenaite | Received |
|
|||
| ABCL-450 | Five-Year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Final Results From the Phase II L-MIND Study | Hanna Bortnik | Received |
|
|||
| CT-452 | Outpatient vs. Inpatient Administration of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Cancer Patients: Systematic Literature Review | Ravi Potluri | Received |
|
|||
| MM-455 | Adjusted Indirect Treatment Comparison of Progression-Free Survival Associated With D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data | Nicole Triolo | Received |
|
|||
| HL-456 | Impact of EBV Status on Outcomes in Hodgkin Lymphoma | Elif Yilmaz | Received |
|
|||
| IBCL-458 | Mosunetuzumab Monotherapy Demonstrates Durable Efficacy With a Manageable Safety Profile in Patients With Relapsed/Refractory Follicular Lymphoma who Received &8805;2 Prior Therapies: Updated Results From a Pivotal Phase II Study | Amy Travis | Received |
|
|||
| MDS-460 | Efficacy of Pacritinib for Spleen, Symptoms, and Anemia Benefit in Myelofibrosis Patients Across the Cytopenic Spectrum | Phoebe Davis | Received |
|
|||
| MM-464 | LocoMMotion: A Prospective, Observational, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma?Final Analysis at 2-Year Follow-up | Mary Baugh | Received |
|
|||
| MM-465 | In-Class Transition (iCT) from Parenteral Bortezomib-based Induction to All-oral Ixazomib-Lenalidomide-Dexamethasone in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma (NDMM): Updated Subgroup Analysis from the Community-Based US MM-6 | Beckie Hopper | Received |
|
|||
| MCL-467 | Glofitamab Monotherapy Induces High Complete Response Rates in Patients With Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma | Amy Travis | Received |
|
|||
| MDS-472 | Clonal Hematopoiesis in Inflammatory Bowel Diseases | Daniel Nathan | Received |
|
|||
| AML-477 | Real-World Treatment Patterns and Patient Characteristics Among Patients with Acute Myeloid Leukemia (AML) in the USA, UK, and France | Emily Eagles | Received |
|
|||
| ABCL-478 | Glofitamab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma and &8805;2 Prior Therapies: Results From a Pivotal Phase II Expansion Study | Amy Travis | Received |
|
|||
| AML-481 | A Multiomic, Single-Cell Measurable Residual Disease (scMRD) Assay For Phasing DNA Mutations and Surface Immunophenotypes | Charlie Murphy | Received |
|
|||
| ABCL-482 | Five-Year Subgroup Analysis of Tafasitamab Lenalidomide From the Phase II L-MIND Study in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Hanna Bortnik | Received |
|
|||
| ABCL-484 | First Use of Upfront Polatuzumab Vedotin in Post-Transplant Lymphoproliferative Disorder | Paranji Sreshta | Received |
|
|||
| ABCL-486 | A Focus on Cancer-Related Cachexia and Sarcopenia in Hematologic Malignancies | Tinsley-Vance Sara | Received |
|
|||
| MDS-488 | Magrolimab Alters the Tumor Microenvironment to Improve Bone Marrow Functions in Patients With Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) | Shannon Daugherty | Received |
|
|||
| IBCL-489 | Mosunetuzumab Retreatment Is Effective and Well-Tolerated in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Amy Travis | Received |
|
|||
| IBCL-492 | A Cost-effectiveness Analysis of Mosunetuzumab for Treatment of Third- or Higher-Line Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in the United States (US) | Amy Travis | Received |
|
|||
| MM-493 | Progression-Free Survival of Daratumumab vs. Bortezomib Triplet Combination with Lenalidomide and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: TAURUS Chart Review Study | Mary Angelozzi | Received |
|
|||
| MPN-498 | Addition of Navitoclax to Ruxolitinib for Myelofibrosis Patients With Relapsed/Refractory Disease and Suboptimal Response to Ruxolitinib Monotherapy: REFINE Cohort 1 Dose Escalation and Expansion | Beth Stapleton | Received |
|
|||
| MM-501 | Overexpression of Proteasome PSMC ATPases Mitigates ER Stress and Correlates With Reduced Overall Survival in Multiple Myeloma | James Ignatz-Hoover | Received |
|
|||
| ABCL-504 | Population Health and Economic Benefits of Pola-R-CHP versus R-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma in the United States | Samuel Bunting | Received |
|
|||
| MM-506 | Novel Proteasome Activators That Enhance MHC Class I Antigen Presentation and Trigger Anti-Myeloma T-Cell Immunity | Priyanka Rana | Received |
|
|||
| CML-511 | T-Cell Exhaustion and Immune Checkpoint VISTA Overexpression Are Associated With Suboptimal Response to Tyrosine Kinase Inhibitors (TKIs) in Patients With Chronic Myeloid Leukemia (CML) | Aram Bidikian | Received |
|
|||
| MPN-512 | Inpatient Resource Utilization and Costs Associated With Hospitalizations for Thromboembolic Events Among Patients With Polycythemia Vera | Brian Hoenig | Received |
|
|||
| ABCL-517 | Phase III Trial of Subcutaneous Epcoritamab R-CHOP Versus R-CHOP Alone in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): EPCORE DLBCL-2 | Sara Cecere | Received |
|
|||
| AML-519 | Sequential Allogeneic Stem Cell Transplantation (alloSCT) After Venetoclax (Ven)-Based Therapy for Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or Myelodysplastic Syndrome With Excess Blasts 2 (MDS-EB2) | Guoda Daukelaite | Received |
|
|||
| MPN-524 | Reductions in Indolent Systemic Mastocytosis Biomarker Burden With Avapritinib in the Registrational, Double-Blind, Placebo-Controlled PIONEER Trial | Michelle Seddon | Received |
|
|||
| MM-527 | Real World Evaluation of Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM) | Asoori Maringanti Sireesha | Received |
|
|||
| AML-530 | Sequential Salvage Chemotherapy and Lintuzumab-Ac225 in Relapsed/Refractory AML Results in Deep Responses and Prolonged Survival in Adverse Risk Acute Myeloid Leukemia (AML) and in AML Patients that Received Prior Venetoclax Therapy | Sameem Abedin | Received |
|
|||
| MPN-531 | Direct and Indirect Costs For Patients With Myeloproliferative Neoplasms (MPNs) | Brian Hoenig | Received |
|
|||
| CML-536 | Apparent Cure for Chronic Myeloid Leukemia (CML): Treatment-Free Remission at Academic Centers in Hungary | Daniel Daniel | Received |
|
|||
| MPN-540 | Disease Progression and Leukemic Transformation in Patients With Lower-Risk Myelofibrosis: An Analysis From the Myelofibrosis and Essential Thrombocythemia Observational Study (MOST) | Catrina Tice | Received |
|
|||
| CLL-542 | High Rates of Undetectable Minimal Residual Disease Remissions with Time-Limited Bendamustine, Rituximab, and Venetoclax (BR-VR) in Untreated Chronic Lymphocytic Leukemia (CLL) an Updated Analysis | Andrew Lipsky | Received |
|
|||
| AML-547 | Prognostic Effect of Co-Mutations on Patients With NPM1 Acute Myeloid Leukemia (AML) Enrolled in the Connect Myeloid Registry | Marybeth McKenzie | Received |
|
|||
| MPN-548 | Phase 1/2 Study of the Activin Receptor-like Kinase 2 (ALK2) Inhibitor Zilurgisertib (INCB000928, LIMBER-104) as Monotherapy or With Ruxolitinib in Patients With Anemia Due to Myelofibrosis | Ruby Spargo | Received |
|
|||
| MPN-549 | Transfusion-Related Cost and Time Burden Offsets in Patients With Myelofibrosis Treated With Momelotinib vs Best Available Therapy | Martha Shoup | Received |
|
|||
| CML-550 | Imatinib (IMA) Low-Dose Reduction Program (LDRpro) in Chronic Myeloid Leukemia (CML) Ph in a Single Reference Institution in Mexico City: Open Prospective Study With 7-Year Follow-up | Hurtado M Rafael | Received |
|
|||
| MPN-551 | Clinical Outcomes With Momelotinib vs Ruxolitinib in Patients With Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-1 | Martha Shoup | Received |
|
|||
| AML-554 | A Phase III, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine in Previously Untreated Patients With TP53-Mutant Acute Myeloid Leukemia | Shannon Daugherty | Received |
|
|||
| ALL-555 | Acute Lymphocytic Leukemia in Pregnancy, Case Report and Review of the Literature. | Aldarweesh Mariam | Received |
|
|||
| MPN-556 | Treatment Comparison of Hydroxyurea vs Ruxolitinib in Essential Thrombocythemia (ET): A Matched Cohort Analysis | Catrina Tice | Received |
|
|||
| MPN-559 | Bromodomain and Extra-terminal (BET) Inhibitor INCB057643 (LIMBER-103) in Patients With Relapsed or Refractory Myelofibrosis (R/R MF) and Other Advanced Myeloid Neoplasms: A Phase I Study | Ruby Spargo | Received |
|
|||
| MDS-567 | Real-World Analysis of a Large Electronic Medical Record Database of Patients With Higher-Risk Myelodysplastic Neoplasms (HR MDN): Treatment Profiles, Clinical Effectiveness, and Key Adverse Event Rates | Shannon Daugherty | Received |
|
|||
| MPN-571 | Effect of New or Worsening Anemia on Clinical Outcomes in Patients With Myelofibrosis (MF) Treated With Ruxolitinib (RUX): A Post Hoc Analysis of the COMFORT-I and -II Trials | Ruby Spargo | Received |
|
|||
| MPN-574 | Characteristics and Clinical Outcomes in Patients With Polycythemia Vera Receiving Ruxolitinib After Hydroxyurea: A Longitudinal Analysis From the Prospective Observational Study of Patients With Polycythemia Vera in US Clinical Practices Trial (REVEAL) | Catrina Tice | Received |
|
|||
| ABCL-582 | Navigating Methotrexate Shortage in Hematologic Malignancy Patients: A Qualitative Analysis | Sharma Pritika | Received |
|
|||
| CLL-584 | Genomic Alterations and Outcomes with Fixed-Duration Ibrutinib Venetoclax: Results From the Phase 3 GLOW Study in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) | Kim Della Penna | Received |
|
|||
| CLL-585 | Real-World Assessment of Dosing Patterns and Treatment Outcomes in Patients With Chronic Lymphocytic Leukemia Who Initiated First-Line Single-Agent Ibrutinib in an Integrated Claims-Based Database | Kim Della Penna | Received |
|
|||
| CLL-586 | Real-World Dosing Patterns and Outcomes Among Patients With Chronic Lymphocytic Leukemia With or Without Dose Adjustment of First-Line Ibrutinib | Kim Della Penna | Received |
|
|||
| CLL-587 | Real-World Treatment Outcomes in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Were Treated With First-Line Single-Agent Ibrutinib vs Chemoimmunotherapy | Kim Della Penna | Received |
|
|||
| CML-593 | The Novel BCR::ABL1 Allosteric Inhibitor HS-10382/TERN-701 is Potent Against Mutations Resistant to Active Site Tyrosine Kinase Inhibitors (TKIs) and Acts Synergistically With TKIs in BCR::ABL1 Cancer Cell Lines | Ben Parsons | Received |
|
|||
| MM-613 | Healthcare Resource Utilization and Costs Among Patients With Relapsed/Refractory Multiple Myeloma Treated With Chimeric Antigen Receptor-T (CAR-T) Cell Therapy | mary baugh | Received |
|
|||
| MDS-614 | Causes of Death in Patients With Myelodysplastic Syndrome and Spliceosome Mutations | Kontoyiannis Panayiotis | Received |
|
|||
| MM-619 | Estimating the Size of Patients With Relapsed/Refractory Multiple Myeloma Treated With 1-3 and 4 or More Prior Lines of Therapy in the United States | mary baugh | Received |
|
|||
| ABCL-620 | Exploring Sexual Dysfunction and Sexual Distress in Patients with Lymphoma During Cancer Treatment | Dorothie Durosier Mertilus | Received |
|
|||
| MM-626 | A Rare Presentation of a Rare Disease, A Case Report of Breast Plasmacytoma | Elbogdady Mohamed | Received |
|
|||
| MPN-628 | Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs Anagrelide as Second Line Therapy in Essential Thrombocythemia | Claire Phillips | Received |
|
|||
| CT-630 | Real World Evaluation of Teclistamab: A Focus on Infections in Patients With Relapsed Refractory Multiple Myeloma (RRMM) | Sireesha Asoori Maringanti | Received |
|
|||
| ABCL-631 | Tumor Lysis Syndrome in Leukemias and Lymphomas: A Retrospective Cohort Study of the National Inpatient Sample from 2016 to 2019 | Daniel Zaldumbide | Received |
|
|||
| CT-632 | Orca-Q Demonstrates Favorable Graft-Versus-Host Disease (GvHD) and Relapse-Free Survival With Haploidentical Donors Without Post-Transplant Cyclophosphamide | Irene Agodoa | Received |
|
|||
| MPN-633 | EXCEED-ET: A Single-Arm Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft in North American Adults With Essential Thrombocythemia | Claire Phillips | Received |
|
|||
| HL-642 | Does Interim PET Assessment After Two Cycles of Treatment With Brentuximab Vedotin Still Have a Predictive Value in Hodgkin Lymphoma? | Ravand Samaeekia | Received |
|
|||
| AML-643 | Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease (GvHD) and Toxicity | Irene Agodoa | Received |
|
|||
| AML-657 | The Association Between Occupational Relevance and Survival in Acute Myeloid Leukemia | Daehun Kwag | Received |
|
|||
SOHO 2023
September 6-9, 2023 Houston
Search and consult posters online
in an exclusive section
for each poster
in an exclusive section
for each poster
ACTIVE FROM 06/09/2023 TO 09/09/2023
Poster
Gallery
Gallery
Upload
Poster
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
Forum
|
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.
|
|
||
|
||||
|
|
